Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.
Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.
复制标题
DOI：
10.1016/j.trsl.2011.08.003
复制
发表时间：
2012-05
期刊：
影响因子：
--
通讯作者：
Garner HR
中科院分区：
文献类型：
--
作者：
Uhr JW;Huebschman ML;Frenkel EP;Lane NL;Ashfaq R;Liu H;Rana DR;Cheng L;Lin AT;Hughes GA;Zhang XJ;Garner HR
我们开发了一种高光谱显微成像（HMI）平台，可以在单次通过中精确识别和量化单个癌细胞中的10种分子标记物。循环肿瘤细胞的改进分离的开发和HMI的应用提供了鉴定这些细胞中的分子变化、识别这些标志物的共表达的机会，并且为非侵入性诊断和靶向治疗的使用提供了重要机会。我们平衡了与10种不同抗体结合的10种荧光染料的强度，每种抗体对特定的肿瘤标志物具有特异性，因此可以从重叠发射中辨别出每种荧光染料的强度。使用来自每个原发性乳腺癌的2个触摸制备物，25个肿瘤细胞的平均分子标记强度给出了肿瘤的代表性分子特征，尽管存在一些细胞异质性。由HMI确定的强度与细胞病理学专家的常规0 - 3+分析很好地相关。由于可以使用相同的荧光染料但不同的抗体开发额外的多重，该分析允许对单个肿瘤细胞上的大量分子标记物进行定量。HMI可以完全自动化，最终可以实现蛋白质生物标志物的标准化，并提高临床病理学实验室的重现性。
We have developed a hyperspectral microscopic imaging (HMI) platform that can precisely identify and quantify 10 molecular markers in individual cancer cells in a single pass. Exploitation of an improved separation of circulating tumor cells and the application of HMI has provided an opportunity to identify molecular changes in these cells, the recognition of co-expression of these markers, and poses an important opportunity for non-invasive diagnosis, and the use of targeted therapy. We have balanced the intensity of 10 fluorochromes bound to 10 different antibodies, each specific to a particular tumor marker, so that the intensity of each fluorochrome can be discerned from overlapping emissions. Using 2 touch preps from each primary breast cancer, the average molecular marker-intensities of 25 tumor cells gave a representative molecular signature for the tumor despite some cellular heterogeneity. The intensities determined by the HMI correlate well with the conventional 0-3+ analysis by experts in cellular pathology. Since additional multiplexes can be developed using the same fluorochromes but different antibodies, this analysis allows quantification of a large number of molecular markers on individual tumor cells. HMI can be completely automated and, eventually, could allow standardization of protein biomarkers and improve reproducibility among clinical pathology laboratories.
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
DOI：
10.1186/bcr1783
发表时间：
2007
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Fehm T;Becker S;Duerr-Stoerzer S;Sotlar K;Mueller V;Wallwiener D;Lane N;Solomayer E;Uhr J
通讯作者：
Uhr J
DOI：
10.1158/1078-0432.ccr-09-3358
发表时间：
2010-08-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Katz RL;He W;Khanna A;Fernandez RL;Zaidi TM;Krebs M;Caraway NP;Zhang HZ;Jiang F;Spitz MR;Blowers DP;Jimenez CA;Mehran RJ;Swisher SG;Roth JA;Morris JS;Etzel CJ;El-Zein R
通讯作者：
El-Zein R
影响因子：
50.3
作者：
Shipitsin, Michail;Campbell, Lauren L.;Polyak, Kornelia
通讯作者：
Polyak, Kornelia
影响因子：
45.3
作者：
Petricoin, EF;Bichsel, VE;Liotta, LA
通讯作者：
Liotta, LA